256 related articles for article (PubMed ID: 38392072)
1. Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology.
Batra A; Glick D; Valdes M
Curr Oncol; 2024 Feb; 31(2):1047-1062. PubMed ID: 38392072
[TBL] [Abstract][Full Text] [Related]
2. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Management of Metastatic Prostate Cancer.
Sayegh N; Swami U; Agarwal N
JCO Oncol Pract; 2022 Jan; 18(1):45-55. PubMed ID: 34473525
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
6. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract][Full Text] [Related]
7. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
8. Novel breakthroughs in advanced prostate cancer management.
Lilly E; Sarkis J; Mahmoud O; El Gharib K; Sarkis P; Nemr E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):369-373. PubMed ID: 36951118
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Flippot R; Patrikidou A; Aldea M; Colomba E; Lavaud P; Albigès L; Naoun N; Blanchard P; Terlizzi M; Garcia C; Bernard-Tessier A; Fuerea A; Di Palma M; Escudier B; Loriot Y; Baciarello G; Fizazi K
Drugs; 2022 May; 82(7):719-733. PubMed ID: 35511402
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
11. Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors.
Maiorano BA; Conteduca V; Catalano M; Antonuzzo L; Maiello E; De Giorgi U; Roviello G
Crit Rev Oncol Hematol; 2023 Dec; 192():104157. PubMed ID: 37863403
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
13. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
14. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
15. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
[TBL] [Abstract][Full Text] [Related]
16. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
17. Use of PARP inhibitors in prostate cancer: from specific to broader application.
Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
[TBL] [Abstract][Full Text] [Related]
18. Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
De Giorgi U; Giunta EF; Verzoni E; Procopio G
Ann Oncol; 2023 Sep; 34(9):729-731. PubMed ID: 37406813
[No Abstract] [Full Text] [Related]
19. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of metastatic prostate cancer.
Gebrael G; Fortuna GG; Sayegh N; Swami U; Agarwal N
Trends Cancer; 2023 Oct; 9(10):840-854. PubMed ID: 37442702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
